Loading company
Addex Therapeutics Ltd
ADXN · Nasdaq · ·
$2.81-23.0%Sep 28 close
- 1M
- -26.8%
- 6M
- -55.7%
- 1Y
- -70.3%
- 5Y
- -98.5%
ADXN · Nasdaq · ·
$2.81-23.0%Sep 28 close
The quarter ending June 30, 2025, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2025 | 3 months toJun 30, 2023 | Change |
|---|---|---|---|
| Profit | -$2.2M | -$3.2M | +31.18% |
| Profit per share | -$0.02 | -$0.17 | +85.71% |
| Free Cash Flow | -$2.7M | -$3.1M | +11.95% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Addex Therapeutics Ltd has no earnings call transcript available.
“The successful raising of USD 2.8 million during the last quarter enables us to continue advancing our in-house GABAB cough program towards clinical development. Coupled with recent regaining of all rights to the GABAB PAM program for substance use disorders from Indivior, due to R&D rationalization following its merger with Supernus Pharmaceuticals, providing a valuable asset for Addex and solidifying our leading portfolio of drug candidates targeting GABAB receptor biology . Our spin-out company, Neurosterix made as well great progress and is on track to complete its Phase 1 clinical study with NTX-253, an M4 positive allosteric modulator with potential in schizophrenia, during the fourth quarter of 2026,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex’s lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is a Phase 2 ready asset under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex is developing a GABAB PAM drug candidate for substance use disorders that has successfully completed IND enabling studies and a second GABAB PAM program for chronic cough, which is ready to start IND enabling studies. Addex holds a 20% equity interest in a private spin-out company, Neurosterix US Holdings LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, psychosis and mood-related disorders, and a mGlu7 NAM for mood disorders. In addition, Addex has invested in Stalicla, a private Swiss company pioneering a precision medicine approach for neurodevelopmental and neuropsychiatric disorders. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol “ ADXN ” on each exchange.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from the 6-K Addex Therapeutics Ltd filed on September 28, 2026 with its results; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.